A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells

BACKGROUND: Chimeric antigen receptor - T (CAR-T) cell therapy has shown remarkable efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). However, a subset of patients still experienced progression or relapse, and the predictors of prognosis are little known. We analyzed the infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yang, Jie, Xingxing, Nian, Li, Wang, Ying, Wang, Congyue, Ma, Jin, Jiang, Jingjing, Wu, Qingyun, Qiao, Jianlin, Chen, Wei, Cao, Jiang, Yan, Zhiling, Shi, Ming, Cheng, Hai, Zhu, Feng, Sang, Wei, Li, Depeng, Chen, Chong, Xu, Kailin, Li, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154462/
https://www.ncbi.nlm.nih.gov/pubmed/37153543
http://dx.doi.org/10.3389/fimmu.2023.1169071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154462/
https://www.ncbi.nlm.nih.gov/pubmed/37153543
http://dx.doi.org/10.3389/fimmu.2023.1169071

Ejemplares similares